Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 341

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 341
---
 Series C preferred stock |     | $                       |       — |   |     | $    |  35,731 |   |
| Warrants issued to placement agent                                                   |     | $                       |       — |   |     | $    |      44 |   |
| Warrants issued to redeemable convertible Series B preferred stockholders            |     | $                       |       — |   |     | $    |      33 |   |
| Right of use assets in exchange for operating lease liabilities                      |     | $                       |   2,405 |   |     | $    |       — |   |
| Acquisition of leasehold improvements                                                |     | $                       |   1,158 |   |     | $    |       — |   |

See accompanying notes to financial statements. F-7

LB Pharmaceuticals Inc

Notes to Financial Statements

1. Business Overview

LB Pharmaceuticals Inc (the “Company” or “LB”) was incorporated under the laws of the State of Delaware in September 2015 and is
headquartered in New York, New York.

The Company is a clinical-stage biopharmaceutical company developing therapies for the treatment of
schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the
Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase
3-ready oral, small molecule for the treatment of acute schizophrenia (defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms).

Since the Company’s inception, it has focused substantially all of its efforts and financial resources on organizing and staffing the Company,
raising capital, building its intellectual property portfolio, undertaking preclinical studies and clinical trials and providing general and administrative support for these activities. The Company has not generated any product revenue related to
its primary business purpose to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, regulatory approval of product candidates, uncertainty of market acceptance of
products, if approved, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and the need to obtain adequate additional
financing to fund the development of its product candidates.

Going Concern

The Company’s financial